» Articles » PMID: 1702384

The Actions of Cyclosporin A and FK506 Suggest a Novel Step in the Activation of T Lymphocytes

Overview
Journal EMBO J
Date 1990 Dec 1
PMID 1702384
Citations 94
Authors
Affiliations
Soon will be listed here.
Abstract

Cyclosporin A and FK506 are immunosuppressive compounds that have similar inhibitory effects on the expression of several lymphokines produced by T lymphocytes. Despite their similar effects the drugs bind to two different cytosolic protein, cyclophilin and FKBP respectively, which raises the possibility that they have different modes of action. Using constructs in which mRNA production controlled by a specific transcription factor could be readily measured we found that both cyclosporin A and FK506 completely inhibited transcription activated by NF-AT, NFIL2 A, NFIL2 B and partially inhibited transcription activated by NF kappa B. Cyclosporin A and FK506 inhibited only transcriptional activation that was dependent on Ca2+ mobilization. However, cyclosporin A and FK506 did not inhibit Ca2+ mobilization dependent expression of c-fos mRNA indicating that only a subset of signalling pathways regulated by Ca2+ is sensitive to these drugs. Furthermore, we did not observe any qualitative differences between the effect of cyclosporin A and FK506 on six different transcription factors which suggests that these drugs may interfere with the activity of a novel Ca2+ dependent step that regulates several transcription factors.

Citing Articles

Transcriptional regulation in the absence of inositol trisphosphate receptor calcium signaling.

Young M, Booth D, Smith D, Tigano M, Hajnoczky G, Joseph S Front Cell Dev Biol. 2024; 12:1473210.

PMID: 39712573 PMC: 11659226. DOI: 10.3389/fcell.2024.1473210.


Immunosuppressant therapy averts rejection of allogeneic FKBP1A-disrupted CAR-T cells.

Maldini C, Messana A, Bendet P, Camblin A, Musenge F, White M Mol Ther. 2024; 32(10):3485-3503.

PMID: 39222637 PMC: 11489550. DOI: 10.1016/j.ymthe.2024.06.022.


Targeting CaN/NFAT in Alzheimer's brain degeneration.

Mackiewicz J, Lisek M, Boczek T Front Immunol. 2023; 14:1281882.

PMID: 38077352 PMC: 10701682. DOI: 10.3389/fimmu.2023.1281882.


Multifaceted control of T cell differentiation by STIM1.

Gross S, Womer L, Kappes D, Soboloff J Trends Biochem Sci. 2023; 48(12):1083-1097.

PMID: 37696713 PMC: 10787584. DOI: 10.1016/j.tibs.2023.08.006.


Beta-Cell Dysfunction Induced by Tacrolimus: A Way to Explain Type 2 Diabetes?.

Rodriguez-Rodriguez A, Porrini E, Torres A Int J Mol Sci. 2021; 22(19).

PMID: 34638652 PMC: 8509035. DOI: 10.3390/ijms221910311.


References
1.
Melton D, Krieg P, Rebagliati M, Maniatis T, Zinn K, Green M . Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter. Nucleic Acids Res. 1984; 12(18):7035-56. PMC: 320141. DOI: 10.1093/nar/12.18.7035. View

2.
Shaw J, Utz P, Durand D, Toole J, Emmel E, Crabtree G . Identification of a putative regulator of early T cell activation genes. Science. 1988; 241(4862):202-5. DOI: 10.1126/science.3260404. View

3.
Elliott J, Lin Y, Mizel S, Bleackley R, Harnish D, Paetkau V . Induction of interleukin 2 messenger RNA inhibited by cyclosporin A. Science. 1984; 226(4681):1439-41. DOI: 10.1126/science.6334364. View

4.
Bickel M, Tsuda H, Amstad P, Evequoz V, Mergenhagen S, Wahl S . Differential regulation of colony-stimulating factors and interleukin 2 production by cyclosporin A. Proc Natl Acad Sci U S A. 1987; 84(10):3274-7. PMC: 304851. DOI: 10.1073/pnas.84.10.3274. View

5.
Brandl C, Deber C . Hypothesis about the function of membrane-buried proline residues in transport proteins. Proc Natl Acad Sci U S A. 1986; 83(4):917-21. PMC: 322981. DOI: 10.1073/pnas.83.4.917. View